Medindia

X

Pipeline of Gastric Ulcers Market Reviewed for H1 2016 in New Global Research Report

Monday, May 2, 2016 Research News J E 4
Advertisement

PUNE, India, May 2, 2016 /PRNewswire/ --

New market research report titled "Gastric Ulcers - Pipeline Review, H1 2016" help enhance decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Company Profiles discussed in this report includes Astellas Pharma Inc., ChoDang Pharm Co., Ltd., Daewoong Pharmaceutical Co., Ltd., Kukje Pharmaceutical Industry Co., Ltd., PharmaReaserch Products Co., Ltd. and Sihuan Pharmaceutical Holdings Group Ltd. Drugs Profiles discussed in this report includes (ecabet + ranitidine), anaprazole sodium, ASP-6537, DWJ-206, KJ-14001, PMKS-005, PRD-007 and Small Molecules for Gastric Ulcers.

Complete report on H1 2016 pipeline review of Gastric Ulcers with 20 market data tables and 10 figures, spread across 45 pages is available at http://www.rnrmarketresearch.com/gastric-ulcers-pipeline-review-h1-2016-market-report.html .

This report provides comprehensive information on the therapeutic development for Gastric Ulcers, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastric Ulcers and special features on late-stage and discontinued projects.

Scope of this report: The report provides a snapshot of the global therapeutic landscape of Gastric Ulcers. The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities and also key players involved in the therapeutics development for Gastric Ulcers and enlists all their major and minor projects summarizing all the dormant and discontinued pipeline projects. A review of the Gastric Ulcers products under development by companies and universities/research institutes based on information derived from company and industry-specific sources, pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages, detailed assessment of monotherapy and combination therapy pipeline projects, coverage of the Gastric Ulcers pipeline on the basis of target, MoA, route of administration and molecule type and latest news and deals relating related to pipeline products.

Reasons to buy 

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Gastric Ulcers
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Gastric Ulcers pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Order a copy of Gastric Ulcers - Pipeline Review, H1 2016 market research report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=538754 .

Another newly published market research report titled on Fecal Incontinence - Pipeline Review, H1 2016 provides comprehensive information on the therapeutic development for Fecal Incontinence, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fecal Incontinence and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Fecal Incontinence Pipeline market research report of 43 pages is available at http://www.rnrmarketresearch.com/fecal-incontinence-pipeline-review-h1-2016-market-report.html .

Explore more reports on Gastrointestinal therapeutics.

About Us:   

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact: Ritesh Tiwari UNIT no 802, Tower no. 7, SEZ Magarpatta city, Hadapsar Pune - 411013 Maharashtra, India. Tel:  +1-888-391-5441 sales@rnrmarketresearch.com

Connect with Us:  G+ / Google Plus: https://plus.google.com/104156468549256253075/posts Twitter: https://twitter.com/RnRMR Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345 RSS / Feeds: http://www.rnrmarketresearch.com/feed

SOURCE RnR Market Research

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
College Choice Releases 2016 Ranking of the Best O...
S
Merck Expands Production Know-how to Deliver Full ...